Allergan, which is a unit of AbbVie (ABBV) agreed to pay up to $200 million to resolve allegations made by New York state and two of its counties that the company helped fuel the opioid crisis and in the process, created a public nuisance that cost billions of dollars in public services.
As a result, Allergan is no longer part of a trial that is close to completion. The case is continuing against Teva Pharmaceutical (TEVA), which has denied the charges. Several other pharmaceutical makers and wholesalers previously settled with the state, including Johnson & Johnson (JNJ), Endo International (ENDP), McKesson (MCK), Cardinal Health (CAH), and AmerisourceBergen (ABC). So far, the state has negotiated $1.7 billion in settlements over the opioid crisis.
Create a display name to comment
This name will appear with your comment